In December 2013, the EMA European Commission granted vortioxetine the right to sell in the entire European Union. There are four specifications for vortioxetine: 5mg, 10mg, 15mg, 20mg. At present, vortioxetine hydrobromide has submitted listing applications in many countries, but has not been listed in my country.Vortioxetine hydrobromide is considered to be a new multi-model antidepressant drug. In vitro studies have shown that it can antagonize 5-HT3, 5-HT7 and 5-HT1D receptors, activate 5-HT1A receptors, and partially activate 5- HT1B receptor and inhibit 5-HT transport.Vortioxetine hydrobromide is a new type of bisarylsulfanylamine antidepressant jointly developed by Takeda Japan and Lingbei, Denmark. It is used in the treatment of depression and anxiety.
Product Categories : Vortioxetine Hydrobromide